Beckman Coulter Inc. said on Tuesday that its Access AccuTnI cardiac troponin I test has received US Food and Drug Administration (FDA) approval for use by clinicians in determining a patient’s future risk of myocardial infarction and for assessment of myocardial damage.
AccuTnI was originally approved by the FDA in 2001 to help diagnose and treat suspected MI. The test measures troponin I that is released by damaged myocardium.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!